Brain Hyperglycosylation Identified as a Key Hallmark of Alzheimer's Disease

Alzheimer's disease is most commonly associated with amyloid plaques and tau tangles, but a growing body of research points to additional molecular disruptions that may be equally important. A new study published via Lifespan.io highlights one such disruption: hyperglycosylation, an abnormal excess of sugar-chain modifications on brain proteins, which researchers now propose as a hallmark feature of Alzheimer's disease.

Using cutting-edge spatial metabolomics, lipidomics, and glycomics technologies, researchers analyzed frontal cortex tissue from deceased Alzheimer's patients and healthy donors. They found significantly elevated glycan levels across both white and grey matter regions in Alzheimer's brains. These findings were replicated in two mouse models of the disease, with changes concentrated in brain regions governing memory, cognitive processing, and neuroinflammation — precisely the areas most devastated by Alzheimer's.

The team determined that this excess glycosylation stems from increased glycan biosynthesis rather than reduced recycling or degradation. Importantly, the modifications occurred predominantly on existing glycoproteins rather than newly glycosylated proteins, and neurons were the primary cell type affected — directly implicating glycosylation in Alzheimer's pathology rather than framing it as a bystander effect.

To test causality, researchers both blocked and amplified glycosylation in mouse models. Reducing N-glycan levels — using either genetic tools or a small molecule inhibitor — led to measurable improvements in social memory performance. This strongly suggests that excessive glycosylation actively contributes to cognitive decline rather than simply reflecting it.

While these results are promising, the research remains preclinical and was conducted in mouse models and post-mortem human tissue. Translation to living human patients requires further validation. Nevertheless, glycosylation pathways represent a novel, potentially druggable target in Alzheimer's disease, and the findings may also inform understanding of how metabolic dysfunction — including altered glucose processing — intersects with neurodegeneration.